<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378038</url>
  </required_header>
  <id_info>
    <org_study_id>PNT2258-04-Richter's</org_study_id>
    <nct_id>NCT02378038</nct_id>
  </id_info>
  <brief_title>PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)</brief_title>
  <official_title>A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sierra Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sierra Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a
      multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to
      characterize anti-tumor activity and collect safety data on patients with Richter's
      Transformation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months</time_frame>
    <description>Safety will be assessed by standard CTCAE criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Richter's Transformation</condition>
  <arm_group>
    <arm_group_label>PNT2258</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNT2258</intervention_name>
    <arm_group_label>PNT2258</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed Richter's transformation (RT) from chronic lymphocytic
             leukemia/small lymphocytic lymphoma (CLL/SLL).

          2. Availability of fresh or archived tumor tissue.

          3. FDG PET-CT (disease) positive baseline scan with measurable disease.

          4. ECOG performance status of 0-1.

          5. Evidence of disease progression at study entry.

          6. Discontinuation of prior anticancer therapy for ≥ 7 days prior to C1D1 and recovered
             to ≤ CTCAE grade 2 (or baseline) from any acute or chronic toxicity associated with
             prior therapy.

          7. Must have previously received at least one prior chemotherapeutic regimen for RT.

             - Previously untreated RT patients deemed ineligible for, or that refuse, intensive
             chemotherapy are eligible.

          8. Adequate bone marrow, renal, and hepatic function.

          9. Normal Coagulation profile.

         10. Agreement to use acceptable methods of contraception during the study and for ≥ 120
             days after the last dose of PNT2258 if sexually active and able to bear or beget
             children.

         11. Ability to participate in the clinical study for a minimum of at least 2 cycles (6
             weeks).

        Exclusion Criteria:

          1. Concurrent non-hematologic malignancies requiring treatment.

          2. No more than 2 prior regimens for DLBCL.

          3. Hodgkin's variant of Richter's lymphoma, accelerated CLL, composite lymphoma,
             interdigitating dendritic cell sarcoma, sarcoma, EBV-associated lymphoma or
             prolymphocytic transformation.

          4. Ongoing risk of bleeding.

          5. CNS or leptomeningeal involvement of lymphoma

          6. Concurrent clinically significant illness, medical condition, surgical history,
             physical finding, electrocardiogram or laboratory finding that, in the opinion of the
             investigator, could adversely affect the safety of the subject or impair the
             assessment of the study results.

          7. Pregnancy or breast-feeding.

          8. Previous exposure to PNT2258.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Klencke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sierra Oncology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Hematology Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNT2258</keyword>
  <keyword>Richter's Transformation</keyword>
  <keyword>NHL</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>Lymphoma, Large B-cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Lymphoma, B-cell</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

